A young woman shares her emotional 15-year journey with hidradenitis suppurativa, chronic skin inflammation for which ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...